Hexarelin is a synthetic hexapeptide and potent GHS-R1a agonist developed as a metabolically stable analogue of GHRP-6. Among the most potent GH secretagogues characterised on a per-mole basis, it is notable for its dual receptor profile: beyond pituitary GH secretion, hexarelin binds to GHS-R1a receptors in the myocardium and also interacts with CD36, a class B scavenger receptor — making it an important research tool for cardiac biology independent of GH effects.
This item is not currently in stock. Message us on Telegram to check availability or place a request.
Join TelegramHexarelin activates GHS-R1a via the same phospholipase C / intracellular calcium mechanism as ipamorelin, producing potent pulsatile GH release. Unlike ipamorelin, hexarelin does not demonstrate the same degree of cortisol/ACTH selectivity — at higher doses, some adrenocortical activation has been observed, limiting its utility in clean endocrine research designs. Its potency on GH release is well characterised in human dose-escalation studies.
Hexarelin's scientifically distinctive property is its cardiac pharmacology. It binds to CD36 — a class B scavenger receptor involved in lipid metabolism and cardiac fatty acid uptake — in the myocardium, independently of GHS-R1a. This dual receptor activity positions hexarelin as a research tool for studying GHS-R1a's cardiac roles and for separately probing CD36-mediated cardiomyocyte signalling.
Preclinical studies have documented cardioprotective effects of hexarelin in ischaemia-reperfusion injury models, with attenuation of left ventricular dysfunction and reduced infarct area. The mechanism appears to involve both direct myocardial GHS-R1a signalling and CD36-mediated fatty acid metabolism modulation in stressed cardiomyocytes.
Multiple dose-escalation trials in healthy human volunteers established hexarelin as one of the most potent GH secretagogues studied in clinical settings. Subcutaneous and intranasal administration produced robust GH pulses across dose ranges, with peak GH responses exceeding those of many other GHRPs at equivalent molar doses.
Some elevation of cortisol and prolactin at higher doses distinguishes hexarelin's selectivity profile from ipamorelin's. This adrenal co-stimulation can be a limiting factor in research designs requiring isolated GH axis assessment, but may be acceptable in protocols focused on overall secretagogue potency or cardiac effects.
CD36 is a transmembrane receptor expressed in cardiomyocytes, endothelial cells, and macrophages, with roles in fatty acid uptake, oxidised LDL recognition, and inflammatory signalling. Hexarelin's ability to bind CD36 independent of GHS-R1a makes it a unique dual-pathway tool for studying the intersection of GH secretagogue biology and cardiac metabolism.
Research in this area has documented that hexarelin can partially protect against ischaemia-reperfusion-induced myocardial damage via mechanisms that appear separable from GH-axis effects — suggesting direct myocardial activity as a research variable independent of systemic GH elevation.